Compare WEX & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEX | TNGX |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | United States | United States |
| Employees | N/A | 137 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.5B |
| IPO Year | 2004 | 2020 |
| Metric | WEX | TNGX |
|---|---|---|
| Price | $165.05 | $28.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $170.18 | $21.78 |
| AVG Volume (30 Days) | 610.6K | ★ 4.5M |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.93 | ★ 26.89 |
| EPS | ★ 2.22 | N/A |
| Revenue | ★ $2,660,800,000.00 | $62,384,000.00 |
| Revenue This Year | $4.93 | N/A |
| Revenue Next Year | $4.55 | N/A |
| P/E Ratio | $73.96 | ★ N/A |
| Revenue Growth | 1.24 | ★ 48.29 |
| 52 Week Low | $125.29 | $5.60 |
| 52 Week High | $186.86 | $34.39 |
| Indicator | WEX | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 69.11 | 50.17 |
| Support Level | $145.44 | $28.13 |
| Resistance Level | $165.13 | $33.96 |
| Average True Range (ATR) | 5.70 | 2.01 |
| MACD | 2.35 | -0.46 |
| Stochastic Oscillator | 95.14 | 27.89 |
WEX Inc is a commerce platform that provides seamlessly embedded, personalized payments solutions. The company operates three business segments: Mobility, Benefits, and Corporate Payments. Mobility segment, the top segment by revenue, provides fleet vehicle payment solutions, transaction processing, and information management services for commercial and government fleets. The Corporate Payments segment offers business-to-business payment processing and transaction monitoring services. The Benefits segment generates revenue from healthcare payment products and its consumer-directed software platform. Its prime end market is the United States of America.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.